93 related articles for article (PubMed ID: 15770730)
1. Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.
Ma JH; Patrut E; Schmidt J; Knaebel HP; Büchler MW; Märten A
World J Gastroenterol; 2005 Mar; 11(10):1521-8. PubMed ID: 15770730
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI).
Schmidt J; Patrut EM; Ma J; Jäger D; Knaebel HP; Büchler MW; Märten A
Cancer Immunol Immunother; 2006 Nov; 55(11):1396-405. PubMed ID: 16485127
[TBL] [Abstract][Full Text] [Related]
3. Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring.
Schmidt J; Jäger D; Hoffmann K; Büchler MW; Märten A
J Immunother; 2007 Jan; 30(1):108-15. PubMed ID: 17198089
[TBL] [Abstract][Full Text] [Related]
4. The treatment of locally advanced pancreatic carcinoma--a dual challenge.
Kjaer M
Radiother Oncol; 1997 Nov; 45(2):105-7. PubMed ID: 9423998
[No Abstract] [Full Text] [Related]
5. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
Zhu Y; Tibensky I; Schmidt J; Hackert T; Ryschich E; Jäger D; Büchler MW; Märten A
J Immunother; 2008 Jan; 31(1):28-33. PubMed ID: 18157009
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].
Knaebel HP; Märten A; Schmidt J; Hoffmann K; Seiler C; Lindel K; Schmitz-Winnenthal H; Fritz S; Herrmann T; Goldschmidt H; Krempien R; Mansmann U; Debus J; Diehl V; Büchler MW
BMC Cancer; 2005 Apr; 5():37. PubMed ID: 15826316
[TBL] [Abstract][Full Text] [Related]
7. The inhibitory effect of cisplatin in combination with irradiation on lung tumor cell growth is due to induction of tumor cell apoptosis.
Fujita M; Fujita T; Kodama T; Tsuchida T; Higashino K
Int J Oncol; 2000 Aug; 17(2):393-7. PubMed ID: 10891552
[TBL] [Abstract][Full Text] [Related]
8. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors.
Vitale G; van Eijck CH; van Koetsveld Ing PM; Erdmann JI; Speel EJ; van der Wansem Ing K; Mooij DM; Colao A; Lombardi G; Croze E; Lamberts SW; Hofland LJ
Ann Surg; 2007 Aug; 246(2):259-68. PubMed ID: 17667505
[TBL] [Abstract][Full Text] [Related]
9. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
Schmidt J; Abel U; Debus J; Harig S; Hoffmann K; Herrmann T; Bartsch D; Klein J; Mansmann U; Jäger D; Capussotti L; Kunz R; Büchler MW
J Clin Oncol; 2012 Nov; 30(33):4077-83. PubMed ID: 23008325
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma.
Zhu Y; Tibensky I; Schmidt J; Ryschich E; Märten A
J Immunother; 2008 Sep; 31(7):599-606. PubMed ID: 18600184
[TBL] [Abstract][Full Text] [Related]
11. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
[TBL] [Abstract][Full Text] [Related]
12. Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.
Huguet F; Fernet M; Giocanti N; Favaudon V; Larsen AK
Target Oncol; 2016 Jun; 11(3):371-81. PubMed ID: 26668065
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant/neoadjuvant chemoradiation for gastric and pancreatic cancer.
Lowy AM; Leach SD
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):121-30. PubMed ID: 10550836
[TBL] [Abstract][Full Text] [Related]
14. Response of pancreatic cancer cells treated with interferon-alpha or beta and co-exposed to ionising radiation.
Jöst E; Roos WP; Kaina B; Schmidberger H
Int J Radiat Biol; 2010 Sep; 86(9):732-41. PubMed ID: 20586542
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antineoplastic activity of a new platinum antineoplastic agent, (R)-(-)-1,1-cyclobutanedicarboxylate (2-aminomethylpyrrolidine)-platinum (II) (DWA2114R) on freshly separated human tumor cells and human tumor xenografts transplanted in nude mice--a comparison with cis-diammine-dichloroplatinum (CDDP).
Nio Y; Imai S; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Tobe T
Anticancer Res; 1991; 11(2):761-7. PubMed ID: 2064331
[TBL] [Abstract][Full Text] [Related]
16. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
18. Chemoradioimmunotherapy with 5-fluorouracil, cisplatin and interferon-alpha in pancreatic and periampullary cancer: results of a feasibility study.
Nitsche M; Horstmann O; Christiansen H; Hermann RM; Hess CF; Becker H; Pradier O; Schmidberger H
Cancer Radiother; 2008 Dec; 12(8):817-21. PubMed ID: 18996727
[TBL] [Abstract][Full Text] [Related]
19. [Effect of cisplatin alone or combined with monoclonal anti-programmed death ligand-1 antibody on lung adenocarcinoma cell line SPCA-1 and T lymphocytes].
Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jun; 37(6):416-20. PubMed ID: 25200040
[TBL] [Abstract][Full Text] [Related]
20. Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum.
Uslu R; Bonavida B
Cancer; 1996 Feb; 77(4):725-32. PubMed ID: 8616765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
